Table 1.
Demographic characteristics
| DEM-TACE | B-TACE | p | |
|---|---|---|---|
| Patient number; nodule number | N:127; N:191 | N: 22; N: 35 | |
| Age, year (mean value ± SD) | 68.6 ± 10.9 | 65.9 ± 13.8 | 0.28 |
| Sex (M/F) | 112/15 | 19/3 | 0.8 |
| Child pugh N (%) | 0.9 | ||
| A5 | 55 (43.3%) | 11 (50.0%) | |
| A6 | 24 (18.9%) | 4 (18.2%) | |
| B7 | 38 (29.9%) | 5 (22.7%) | |
| B8 | 10 (7.9%) | 2 (9.1%) | |
| BCLC N (%) | |||
| A | 84 (66.1%) | 10 (45.5%) | 0.06 |
| B | 43 (33.9%) | 12 (54.5%) | |
| Etiology: N (%) | 0.78 | ||
| HCV | 66 (52%) | 9 (41.0%) | |
| HBV | 22 (17.3%) | 4 (18.2%) | |
| Alcohol related cirrhosis | 17 (13.4%) | 5 (22.7%) | |
| Cryptogenetic cirrhosis | 14 (11%) | 3 (13.6%) | |
| NASH | 8 (6.3%) | 1 (4.5%) | |
| MELD: (mean value ± SD) | 9.9 ± 2.0 | 10.0 ± 2.3 | 0.82 |
| MELDNa: (mean value ± SD) | 10.8 ± 2.6 | 10.8 ± 2.6 | 0.91 |
| AFP serum level μg/L (median IC95%) | 27.5 (1.1–3971) | 6.4 (0.7–2599.0) | 0.65 |
| Indications for TACE | 0.7 | ||
| Downstaging | 20 (15.7%) | 3 (13.6%) | |
| Bridging | 50 (39.4%) | 7 (31.8%) | |
| Palliative | 57 (44.9%) | 12 (54.6%) |
DEM-TACE drug eluting embolics trans-arterial chemoembolization; B-TACE balloon occluded trans-arterial chemoembolization; SD standard deviation; M Male; F Female; BCLC Barcelona clinic liver cancer; HCV Hepatitis C virus; HBV Hepatitis B virus; NASH Non-alcoholic steatohepatitis; MELD Model for End-Stage Liver Disease; AFP α- fetoprotein